SCHEMBL6739359

SCHEMBL6739359

Nc1cccc(S(N)(=O)=O)c1Br

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 12/20 0.61
CA1 P00915 9/20 0.61
CA9 Q16790 8/20 0.61
CA12 O43570 6/20 0.61
CA6 P23280 5/20 0.61
CA4 P22748 5/20 0.61
CA7 P43166 5/20 0.61
CA5A P35218 4/20 0.61
CA5B Q9Y2D0 4/20 0.61
CA14 Q9ULX7 4/20 0.61
CYP2C9 P11712 1/20 0.61
GAA P10253 1/20 0.46
CDK2 P24941 1/20 0.44
TTR P02766 1/20 0.42
HTR6 P50406 1/20 0.41
MAPK1 P28482 1/20 0.40
STAT3 P40763 1/20 0.39
PLCG1 P19174 1/20 0.38
NSD2 O96028 1/20 0.37
CA3 P07451 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL528641 0.82 CA2 (0.67) CA2CA1CA9CA12CA6
SCHEMBL7761041 0.77 CA2 (0.67) CA2CA1CA9CA12CA6
SCHEMBL183126 0.77 CA2 (1.00) CA2CA1CA9CA12CA6
SCHEMBL30074528 0.77 CA2 (1.00) CA2CA1CA9CA12CA6
SCHEMBL15544533 0.76 ALDH1A1 (0.42) CA2CA1CA9CA12CA6
SCHEMBL2542148 0.76 CA2 (0.64) CA2CA1CA9CA12CA6
SCHEMBL6683006 0.76 CA2 (0.64) CA2CA1CA9CA12CA6
SCHEMBL8157845 0.75 GAA (0.44) CA2CA1CA9CA12CA6
Methane SCHEMBL18230300 0.75 CA2 (0.95) CA2CA1CA9CA12CA6
SCHEMBL23364695 0.74 CA2 (0.61) CA2CA1CA9CA12CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4423081-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF The Children's Medical Center Corporation (US) 2024-09-04 EP disclosed
WO-2023086220-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-05-19 WO disclosed
US-6689770-B2 AN INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES, AS ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-02-10 US disclosed
EP-1175419-B1 ARYL SULFONYLS AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB PHARMA CO (US) 2003-05-28 EP disclosed
US-20030050315-A1 Aryl sulfonyls as factor Xa inhibitors WEXLER RUTH R (US) 2003-03-13 US disclosed
US-6399644-B1 ANTICOAGULANTS DUPONT PHARMACEUTICALS COMPANY 2002-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050315-A1 Aryl sulfonyls as factor Xa inhibitors F12, F11, TFPI CA2 2573/4885CA1 2249/4885CA9 931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.